The percentage on each card is CLYM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 t…
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it…
● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that me…
● GlobeNewsWireOct 24, 2026 · 19:30 ETCOMPANY'S OWN WORDS
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027…
● GlobeNewsWireOct 23, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first …
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash, providing operational runway…
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.…
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.…
● GlobeNewsWireSep 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting to…
● GlobeNewsWireSep 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that m…
Article counts from the last market-wide feed page, across every symbol we track and not just CLYM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.